Search Results

There are 7071 results for: content related to: The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype

  1. You have free access to this content
    Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 69, Issue 5, May 2010, Pages: 508–515, Mohi Iqbal Mohammed Abdul, Xuemin Jiang, Kenneth M. Williams, Richard O. Day, Basil D. Roufogalis, Winston S. Liauw, Hongmei Xu, Anita Matthias, Reginald P. Lehmann and Andrew J. McLachlan

    Version of Record online : 28 JAN 2010, DOI: 10.1111/j.1365-2125.2010.03620.x

  2. Influence of CYP2C9 and VKORC1 Polymorphisms on Warfarin and Acenocoumarol in a Sample of Lebanese People

    The Journal of Clinical Pharmacology

    Volume 51, Issue 10, October 2011, Pages: 1418–1428, Ms Maria O. Esmerian, Dr Zahi Mitri, Dr Mohammad-Zuheir Habbal, Mr Eddy Geryess, Dr Ghazi Zaatari, Dr Samir Alam, Dr Hadi N. Skouri, Dr Rami A. Mahfouz, Dr Ali Taher and Dr Nathalie K. Zgheib

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270010382910

  3. You have free access to this content
    The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies –CYP2C9 and warfarin as an example

    British Journal of Clinical Pharmacology

    Volume 64, Issue 1, July 2007, Pages: 14–26, Gemma L. Dickinson, Martin S. Lennard, Geoffrey T. Tucker and Amin Rostami-Hodjegan

    Version of Record online : 12 FEB 2007, DOI: 10.1111/j.1365-2125.2007.02850.x

  4. A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy

    Clinical Pharmacology & Therapeutics

    Volume 81, Issue 4, April 2007, Pages: 529–538, A-K Hamberg, M-L Dahl, M Barban, M G Scordo, M Wadelius, V Pengo, R Padrini and E N Jonsson

    Version of Record online : 14 FEB 2007, DOI: 10.1038/sj.clpt.6100084

  5. Tecarfarin, a Novel Vitamin K Reductase Antagonist, Is Not Affected by CYP2C9 and CYP3A4 Inhibition Following Concomitant Administration of Fluconazole in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 51, Issue 4, April 2011, Pages: 561–574, Dr Linda M. Bavisotto, Dr David J. Ellis, Dr Peter G. Milner, Mr Daniel L. Combs, Mr Ian Irwin and Dr Daniel M. Canafax

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010370588

  6. You have free access to this content
    Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin

    British Journal of Clinical Pharmacology

    Volume 74, Issue 5, November 2012, Pages: 797–805, Berit Packert Jensen, Paul Ken Leong Chin, Rebecca Lee Roberts and Evan James Begg

    Version of Record online : 9 OCT 2012, DOI: 10.1111/j.1365-2125.2012.04259.x

  7. You have free access to this content
    Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon

    British Journal of Clinical Pharmacology

    Volume 77, Issue 4, April 2014, Pages: 626–641, Talitha I. Verhoef, William K. Redekop, Ann K. Daly, Rianne M. F. van Schie, Anthonius de Boer and Anke-Hilse Maitland-van der Zee

    Version of Record online : 20 MAR 2014, DOI: 10.1111/bcp.12220

  8. Combination of Phenotype Assessments and CYP2C9-VKORC1 Polymorphisms in the Determination of Warfarin Dose Requirements in Heavily Medicated Patients

    Clinical Pharmacology & Therapeutics

    Volume 83, Issue 5, May 2008, Pages: 740–748, V Michaud, M-C Vanier, D Brouillette, D Roy, L Verret, N Noel, I Taillon, G O‧Hara, D Gossard, M Champagne, K Goodman, Y Renaud, A Brown, M Phillips, AM Ajami and J Turgeon

    Version of Record online : 14 NOV 2007, DOI: 10.1038/sj.clpt.6100434

  9. Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian Patients

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 6, December 2008, Pages: 722–728, JA Perini, CJ Struchiner, E Silva-Assunção, ISC Santana, F Rangel, EB Ojopi, E Dias-Neto and G Suarez-Kurtz

    Version of Record online : 27 AUG 2008, DOI: 10.1038/clpt.2008.166

    Corrected by:

    Corrigendum: CORRIGENDUM: Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian Patients

    Vol. 85, Issue 4, 448, Version of Record online: 7 MAY 2008

  10. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients

    Clinical Pharmacology & Therapeutics

    Volume 80, Issue 2, August 2006, Pages: 169–178, Kyoko Obayashi, Katsunori Nakamura, Junichi Kawana, Hiroyasu Ogata, Kazuhiko Hanada, Masahiko Kurabayashi, Akira Hasegawa, Koujirou Yamamoto and Ryuya Horiuchi

    Version of Record online : 19 AUG 2006, DOI: 10.1016/j.clpt.2006.04.010

  11. You have full text access to this OnlineOpen article
    Characterizing variability in warfarin dose requirements in children using modelling and simulation

    British Journal of Clinical Pharmacology

    Volume 78, Issue 1, July 2014, Pages: 158–169, Anna-Karin Hamberg, Mia Wadelius, Lena E. Friberg, Tina T. Biss, Farhad Kamali and E. Niclas Jonsson

    Version of Record online : 20 JUN 2014, DOI: 10.1111/bcp.12308

  12. A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age

    Clinical Pharmacology & Therapeutics

    Volume 87, Issue 6, June 2010, Pages: 727–734, A-K Hamberg, M Wadelius, J D Lindh, M L Dahl, R Padrini, P Deloukas, A Rane and E N Jonsson

    Version of Record online : 21 APR 2010, DOI: 10.1038/clpt.2010.37

  13. The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans

    Clinical Pharmacology & Therapeutics

    Volume 89, Issue 3, March 2011, Pages: 408–415, MA Perera, E Gamazon, LH Cavallari, SR Patel, S Poindexter, RA Kittles, D Nicolae and NJ Cox

    Version of Record online : 26 JAN 2011, DOI: 10.1038/clpt.2010.322

  14. A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity

    The Journal of Clinical Pharmacology

    Volume 49, Issue 2, February 2009, Pages: 138–146, Myong-Jin Kim, Shiew-Mei Huang, Urs A. Meyer, Atiqur Rahman and Lawrence J. Lesko

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008328098

  15. You have free access to this content
    Pharmacogenomics of warfarin in populations of African descent

    British Journal of Clinical Pharmacology

    Volume 75, Issue 2, February 2013, Pages: 334–346, Guilherme Suarez-Kurtz and Mariana R. Botton

    Version of Record online : 10 JAN 2013, DOI: 10.1111/j.1365-2125.2012.04354.x

  16. Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats

    Journal of Pharmacy and Pharmacology

    Volume 65, Issue 8, August 2013, Pages: 1195–1203, Han Oll Kim, Kyung Eun Lee, Hee Yoon Park, Na Ra Lee, Byeou Ree Oh, Byung Chul Chang and Hye Sun Gwak

    Version of Record online : 28 MAY 2013, DOI: 10.1111/jphp.12084

  17. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

    Clinical Pharmacology & Therapeutics

    Volume 79, Issue 3, March 2006, Pages: 197–205, Soo-Chin Lee, Swee-Siang Ng, Johannes Oldenburg, Pei-Yi Chong, Simone Rost, Jia-Yi Guo, Hui-Ling Yap, Sheila Clare Rankin, Hui-Boon Khor, Tiong-Cheng Yeo, Kheng-Siang Ng, Richie Soong and Boon-Cher Goh

    Version of Record online : 7 FEB 2006, DOI: 10.1016/j.clpt.2005.11.006

  18. You have free access to this content
    Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects

    British Journal of Pharmacology

    Volume 154, Issue 8, August 2008, Pages: 1691–1700, M I Mohammed Abdul, X Jiang, K M Williams, R O Day, B D Roufogalis, W S Liauw, H Xu and A J McLachlan

    Version of Record online : 29 JAN 2009, DOI: 10.1038/bjp.2008.210

  19. You have free access to this content
    Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione

    British Journal of Clinical Pharmacology

    Volume 73, Issue 3, March 2012, Pages: 428–436, Karine Lacut, Estelle Ayme-Dietrich, Lenaick Gourhant, Elise Poulhazan, Marion Andro, Laurent Becquemont, Dominique Mottier, Gregoire Le Gal and Celine Verstuyft

    Version of Record online : 13 FEB 2012, DOI: 10.1111/j.1365-2125.2011.04095.x

  20. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone

    Clinical Pharmacology & Therapeutics

    Volume 66, Issue 6, December 1999, Pages: 569–581, Harumi Takahashi, Teruki Sato, Yoshiaki Shimoyama, Noriko Shioda, Teppei Shimizu, Suzuko Kubo, Noboru Tamura, Hitoshi Tainaka, Toshio Yasumori and Hirotoshi Echizen

    Version of Record online : 19 DEC 1999, DOI: 10.1053/cp.1999.v66.103378001